secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENSAR, Inc. (LNSR)
CIK:        0001320350
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0001564590-22-028304
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LENSAR Q2 revenue $8.0M (+1% YoY), net loss ($6.8M); FDA OK for ALLY system
---------------------------------------------------------------------------

- Net loss of ($6.8M) or ($0.67)/share vs. ($4.4M) or ($0.47)/share in Q2 2021.
- Total procedure volume up 8% to 33,359; U.S. volume up 15% vs. Q2 2021.
- Selling, general & administrative expenses rose 37% to $7.6M; R&D up 28% to $3.8M.
- Adjusted EBITDA (ex stock comp) was ($4.3M) vs. ($2.3M) a year ago.
- FDA cleared ALLY Adaptive Cataract Treatment System in June; expects ~10 U.S. placements in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1320350/000156459022028304/0001564590-22-028304-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1320350/000156459022028304/lnsr-8k_20220808.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-028304

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer